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Evaluation of the suitability of weekly peak 
expiratory flow rate measurements in monitoring 
annual decline in lung function among patients 
with asthma and chronic bronchitis
P R S TIRIMANNA C LA VAN HERWAARDEN which measure peak flow and FEV„ could be used in general
J J DEN OTTER H FOLGERING
C P VAN SCHAYCK C VAN WEEL
practice. These would allow general practitioners to con­
tinue measuring peak flow in order to assess short-term 
changes in lung function while providing an important 
means for monitoring FEV, to assess long-term changes in 
lung function.
Keywords: asthma; airways obstruction; peak expiratory
flow recordinas: iuna function.
SUMMARY
Background. Early detection and treatment of patients with __ _____
asthma or chronic bronchitis who have a rapid annual g ; l g , 
decline in lung function is essential in order to improve 
their long-term prognosis. This annual rate of decline can 
be assessed accurately by monitoring the forced expiratory 
volume in one second (FEV,) which is a routine procedure 
in hospital respiratory laboratories but not in general prac­
tice. General practitioners usually measure patients' peak 
expiratory flow rate (peak flow) to evaluate lung function. If 
annual decline in lung function can be assessed by mon­
itoring peak flow, this method could be used in general 
practice for detecting patients at an early stage who have a 
rapid decline.
Aim. A study aimed to investigate the long-term correlation 
between FEV, and peak flow among a group of patients in 
Nijmegen, the Netherlands.
Method. FEV, and peak flow were monitored in 53 patients 
with moderate asthma and 78 patients with moderate  
chronic bronchitis over four years. FEV, was measured in a 
laboratory once every six months and peak flow was mea­
sured by patients once a week. The correlation between the 
two sets of measurements was studied for each patient.
Results. Four-year data for 83 o f the 131 patients were 
analysed; the other 48 patients received inhaled steroids 
during the second half of the study period so their data 
were not considered for all the analyses. O f the 83 
patients, 35 (42%) showed a decrease in both FEV, and 
peak flow. Thirty six patients (43%) showed a decrease in 
FEV, and an increase in peak flow. Four patients (5%) 
showed an increase in FEV, and a decrease in peak flow 
and eight patients (10%) showed an increase in both rates.
Approximately similar results were seen in a separate 
analysis of all 131 patients during the first two years of the 
study.
Conclusion. No long-term correlation was found between 
FEV, and peak flow. Peak flow is not capable of detecting 
annual decline in lung function. Therefore it cannot be used 
to detect patients with asthma or chronic bronchitis who 
have a rapid annual decline in lung function. Spirometers,
Introduction
HERE is an increased appreciation of the importance of using 
objective parameters such as peak expiratory flow rate (peak 
flow) in the diagnosis and treatment of patients with asthma and 
chronic bronchitis (chronic obstructive pulmonary disease).1,2 The 
peak flow represents the maximum flow of air attained during a 
forced expiratory manoeuvre and corresponds to the peak on a 
ilow-volume curve. This maximum flow during expiration is 
reduced in patients with airway obstruction, for example those 
with asthma or chronic bronchitis. The rate has been shown to be 
a simple and reproducible parameter in assessing airway obstruc­
tion.’ The peak flow meter is a cheap and simple device that is 
commonly used in general practice and by asthmatic patients in 
self-management programmes. A patient’s measured peak flow 
value can be compared with a predicted value (obtained from 
standard reference charts) or with the patient's personal 
(measured during a symptom-free period) to determine the pres­
ence or absence of airway obstruction. Other common uses of 
peak flow measurements are in the assessment of diurnal variabil­
ity, day-to-day variability and reversibility of airway obstruction.’1 
The greater the variability the more prone are the airways to 
bronchial constriction.
The forced expiratory volume in one second (FEV,) is another 
objective parameter which has been established as the best meas­
ure for assessing severity of airway obstruction. '
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complexity and high costs of the necessary apparatus it has 
recently only been used in hospital respiratory laboratories. Since 
the introduction of portable, easy-to-use, low-cost spirometers, 
patients’ FEV, is occasionally being measured in general 
tice. FEV, has been shown to be an important index for assessing 
severity of airway obstruction and for estimating its progression 
and is so far the only parameter that has been shown to predict 
asthma mortality.5 In adults, FEV, shows a physiological decline 
with age.6,7 This annual rate of decline is greater in asthma and 
chronic bronchitis sufferers compared with non-sufferers.1 It is 
possible to detect patients with a high annual rate of decline in 
lung function by means of serial FEV, measurements, 
detection followed by adequate treatment of such patients 
been shown to reduce this rate of decline, thereby improving 
patients’ long-term prognosis.0
FEV, and peak flow measurements show a close correlation in 
cross-sectional studies.10 Although many longitudinal 
have investigated the course of FEV, over time, little is
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about the course of peak flow over time and its long-term corre- Patient symptoms and smoking history
FEV ’ have a close long-term Patients recorded their symptoms on the Dutch version of a
correlation with FEV, it could be used in general practice to Medical Research Council respiratory symptoms questionnaire,
detect patients with a fast, progressive form of asthma or chronic The numbers of symptoms recorded were added together and
bronchitis. A study was carried out to investigate the long-term presented as a score ranging from zero to eight. Smoking history
correlation between FEV, and peak flow.
Method
>
Patient selection and participation
The study was approved by the medical ethics committee of the 
University of Nijmegen, the Netherlands. Twenty nine general 
practitioners in the catchment area of the university selected 
patients for the four-year study. A total of 223 patients aged 30 
years or over with moderate airway obstruction owing to asthma 
or chronic bronchitis were selected for the study.11 Of the 
patients selected, 131 (53 with asthma and 78 with chronic bron­
chitis) completed the four-year follow up during which FEV, and 
peak flow measurements were made.
The only medication allowed during the first two years of the 
study were the bronchodilators salbutamol or ipratropium brom­
ide. At the end of the second year the annual rate of decline in 
FEV, was calculated for each patient by means of regression 
analysis. Patients were then divided into two groups according to 
the magnitude of their annual rate of decline. The first group 
comprised 48 patients with an annual rate of decline in FEV, 
greater than 0.08 1 year1 (26 of whom had asthma). The second 
group comprised the 83 patients whose rate of decline in FEV, 
was less than 0.08 1 year'1 (27 of whom had asthma). 
Beclomethasone dipropionate inhalations 400 n% twice daily 
were added to the medication of all patients in the first group. No 
additional medication was given to patients in the second group. 
Both groups were monitored for a further two years.
was assessed in pack years, a pack year being defined as 25 cigar 
ettes per day per year.
Longitudinal correlation between FEV, and peak flow
Data for all 131 patients were analysed for the first two years of 
the study. Five FEV, and 104 peak flow measurements per 
patient were considered for regression analysis. There were no 
missing values during the first two years. The regression coeffi­
cient of the FEV, and of the peak flow were calculated and the 
former was then plotted against the latter for each patient.
Data for the 83 patients in the group not receiving inhaled cor­
ticosteroids were analysed for the four years of the study. Nine 
FEV, and 208 peak flow measurements per patient were consid­
ered for regression analysis. There was one missing FEV, value 
in the third year and three in the fourth year, thus, four patients 
had eight instead of nine FEV, measurements. In these cases the 
regression coefficient was calculated for the available measure­
ments. For each of the 83 patients, the regression coefficient of 
the FEV, was calculated and plotted against the regression coef­
ficient of the peak flow.
Cross-sectional correlation between FEV, and peak flow
FEV, was measured on nine occasions. Nine corresponding peak 
flow values were obtained by calculating the mean of five con­
secutive weekly peak flow values for each FEV, value (the third 
peak flow value corresponded with the week of FEV, measure­
ment). The mean FEV, and mean peak flow values for patients in 
the first group (that is, patients who received inhaled cortico­
steroids during the third and fourth years of the study) and 
patients in the second group (those who did not receive inhaledFEV,
FEV, measurements were performed once every six months at corticosteroids) were then plotted on a time scale, 
the Department of Pulmonology, Dekkerswald, the Netherlands
by two trained laboratory assistants. FEV, was measured using Patient characteristics associated with a high correlation
an integrating flow meter (Microspiro HI-298®, Chest 
Corporation).12 Patients were instructed to refrain from bron- 
chodilator therapy for at least eight hours before measurement. 
At each measurement three forced expiratory manoeuvres were 
carried out. The difference between the highest and the lowest 
FEV, values had to be less than 0.1 1; if this was not the case, 
patients were asked to try again after a few minutes’ rest. The 
FEV, of the attempt with the highest sum of FEV, and forced 
vital capacity was retained for statistical analysis. All measure­
ments were made during periods free from exacerbations. 
Exacerbations were defined according to Fletcher, modified 
according to Boman and colleagues.13 In total nine half-yearly 
FEV, measurements per patient were available for analysis.
and peak flow
A correlation coefficient of 0.6 or greater between the slopes of a 
patient’s FEV, and peak flow was defined as being a high cor­
relation and a correlation coefficient of less than 0.6 was defined 
as being low. Various patient characteristics, for example age, 
symptom score, number of pack years of cigarettes, bronchial 
hyper-responsiveness and percentage airway reversibility, were 
analysed to determine whether any patient characteristics were 
associated with a high correlation between FEVi and peak flow.
Peak flow
Statistical tests
The difference in the distribution of nominal variables between 
patients who had a high or low correlation coefficient between 
their FEV, and peak flow was tested using the chi square test. 
Continuous variables were tested using the unpaired i-test. The
Peak flow was measured using an Assess® peak flow meter Wilcoxon test was used to test the difference in patients’ 
(Health Scan Products).14 All patients were given a peak flow bronchial hyper-responsiveness.
meter and were taught to measure their own rate. Patients were
same
three times in the morning, and to record all results in a diary 
card. All measurements were made before using bronchodilator
Results
Longitudinal correlation between FEV, and peak flow
medication. The patient’s technique in measuring and recording Two-year follow up. The relationship between the regression
peak flow was checked at each visit to the lung function labora­
tory. The highest of the three peak flow measurements was con­
sidered for analysis. In total, 208 weekly peak flow measure­
ments per patient were available for analysis.
coefficients of the FEV, and of the peak flow for each of the 131 
patients during the first two years of the study is shown in Figure 
1. In total 88 patients (67.2%), of whom 36 had asthma, showed 
a decrease in FEV, and 59 patients (45.0%), of whom 19 had
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Figure 1. Relationship between the regression coefficients of FEV, 
and peak expiratory flow rate (PEFR) for each of the 131 patients
during the first two years of the study, where patients with
asthma and *■ = patients with chronic bronchitis fn = number of 
patients).
asthma, showed a decrease peak flow during this period. Forty 
seven patients (35.9%), 16 of whom had asthma, showed a 
decrease in both FEV, and peak flow. Forty one patients 
(31.3%), 20 of whom had asthma, showed a decrease in FEV, 
and an increase in peak flow. Twelve patients (9.2%), three of 
whom had asthma, showed an increase in FEV, and a decrease in 
peak flow. Thirty one patients (23.7%), 14 of whom had asthma, 
showed an increase in both rates.
Four-year follow up. The relationship between the regression 
coefficients of the FEV, and of the peak ftow for each of the 83 
patients not receiving inhaled corticosteroids followed up over 
four years is shown in Figure 2. In total 71 patients (85.5%), 17 
of whom had asthma, showed a decrease in FEV, and 39 patients 
(47.0%), of whom 13 had asthma, showed a decrease in peak 
flow during this period. Thirty five patients (42.2%), 10 of whom 
had asthma, showed a decrease in both FEV, and peak flow. 
Thirty six patients (43.4%), seven of whom had asthma, showed 
a decrease in FEV, and an increase in peak flow. Four patients 
(4.8%), three of whom had asthma, showed an increase in FEV,
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Figure 2. Relationship between the regression coefficients of FEV1 
and peak expiratory flow rate (PEFR) for each of the 83 patients
during the four-year period, where » patients with asthma
and A = patients with chronic bronchitis (n = number of patients).
and a decrease in peak flow. Eight patients (9.6%), seven of 
whom had asthma, showed an increase in both rates.
Cross-sectional correlation between FEV, and peak flow
The mean FEV, and peak flow values for the 48 patients in the 
first group and the 83 patients in the second group over the four 
years are shown in Figure 3. Patients in the first group showed a 
decline in FEV, of 0.16 1 year1 during the first two years of the 
study while peak flow remained stable. Patients’ FEV, and peak 
flow increased during the initial six months of treatment with 
inhaled corticosteroids (FEV, increased by 0.46 1 year'1). 
Although FEV, decreased after this initial treatment effect (by 
0.10 1 year1) peak flow remained stable. The decline in FEV, 
during this period was 0.06 1 year1 less than the rate of decline 
before treatment with inhaled corticosteroids. FEV, of patients in 
the second group showed a progressive decline over the four years 
of the study while peak flow remained approximately the same.
Patient characteristics associated with a high correlation 
between FEV, and peak flow
A total of 101 patients had a correlation coefficient of less than 
0.6 between their FEV, and peak flow (low correlation group) 
and 30 patients had a correlation coefficient of 0.6 or greater 
(high correlation group). No patient characteristics were found to 
be associated with a high correlation between FEV, and peak 
llow (Table 1). Patient characteristics that were asthma-related 
such as bronchial hyper-responsiveness, reversibility of airway 
obstruction, atopy and a diagnosis of asthma, were associated 
with a high correlation between FEV, and peak flow, but none of 
the characteristics showed a significant difference between the 
two groups.
a long-term con
Discussion
The present study failed to 
between FEV, and peak flow in patients with moderate asthma or 
chronic bronchitis. The majority of patients showed a long-term 
decline in FEV, while only a few showed a decline in peak flow. 
The percentage of patients showing a decline in FEV, increased 
over time. There was, however, only a marginal increase in the 
percentage of patients showing a decline in peak flow. The short­
term effect of inhaled corticosteroid treatment on the level of 
FEV, and peak flow during the first half of the third year showed 
a possible correlation on a group basis. Although asthma patients 
showed a high correlation between peak flow and FEV,, no 
patient characteristics were found that could predict a high corre­
lation between the two rates. Hence it can be concluded that, 
unlike the FEV,, peak flow is not capable of detecting the annual
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Figure 3. Mean FEV, and peak expiratory flow rate (PEFR) values 
for 48 patients In the first group (those taking Inhaled cortico­
steroids in the third and fourth years of the study) and 83 patients 
in the second group (those not taking Inhaled corticosteroids) over 
the four years of the study.
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Table 1. Patient characteristics associated with a high or low  cor­
relation between FEV, and peak expiratory flow rate (PEFR).
Characteristics of group in which 
correlation between FEV, and PEFR
Patient characteristics Low (r< 0.6) High (r  ^ 0.6)
No. of patients 101 30
«
Age (years) 52 50
Sex (no. of men) 59 13
Symptom score 5 5
No. of pack years
of cigarettes 17 15
Smoker (% of group) 56 40
FEV, (I sec’1) 2.4 2.2
FEV, (% of predicted value) 76 73
Bronchial hyper­
responsiveness (PC30)(mg ml'1) 4 2
PEFR (I m in 1) 553 525
Reversibility of
airway obstruction (%) 16 22
Atopy (% of group) 24 33
Asthma (% of group) 36 57
decline in lung function in adults with moderate asthma or chron­
ic bronchitis.
The general practice management of asthma, including self­
management, is based on daily peak flow measurements, where­
by the ‘traffic light’ system of colour-coded peak flow measure­
ment zones provides the patient with an easy to understand 
method of maintaining lung function at the highest possible 
level.1 The effect of appropriate medical intervention can also be 
demonstrated by short-term monitoring of peak flow: the present 
study showed a rise in peak flow during intervention with 
inhaled corticosteroids. Peak flow has also been shown to be a 
reliable measure of the reversibility of airways obstruction.4 
Other investigations have shown a good short-term relationship 
between peak flow and FEV,.10 Peak flow can, therefore, be con­
sidered as a reliable parameter for monitoring short-term changes 
in lung function in patients with asthma or chronic bronchitis.
FEV, provides an integrated index of the maximum flow dur­
ing ±75% of the expiratory flow-volume curve.15 Peak flow 
mainly reflects the conductance in the central airways and is 
responsible for only the initial part of the flow-volume curve. 
Both FEV, and peak flow are known to be effort-dependent and 
relatively insensitive to minor changes in the calibre of peri­
pheral airways. The time span within which the two parameters 
are measured is therefore a possible explanation for the difference 
in sensitivity to minor changes in maximum flow of air.
No long-term correlation was found to exist between peak 
flow and FEV,. The consequence of this fact is of clinical impor­
tance. A patient with a stable peak flow, measured during con­
secutive consultations, can have a rapid decline in FEV, which 
can proceed unnoticed if the FEV, is not assessed. Peak flow is 
therefore not suitable for detecting patients at an early stage who 
have a rapid decline in lung function. Since early detection and 
treatment of patients with asthma or chronic bronchitis is the 
only way to improve the long-term prognosis of these patients, 
general practitioners could consider using a spirometer for mon­
itoring lung function in adults. Modem portable spirometers are 
inexpensive and easy to use. In the near future much cheaper and 
more accurate spirometers are expected. Almost all portable 
spirometers also measure peak flow. Such an instrument would 
allow general practitioners to continue measuring peak flow in 
order to assess short-term changes in lung function while provid­
ing an important means for monitoring FEV, for the assessment 
of long-term changes in lung function.
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